Rapport Therapeutics (RAPP) announced that it has commenced an underwritten public offering of $250M of shares of its common stock. Goldman Sachs & Co. LLC, Jefferies, TD Cowen and Stifel are acting as joint book-running managers for the proposed offering.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RAPP:
- Rapport Therapeutics price target raised to $56 from $35 at Stifel
- EchoStar sells spectrum licenses to SpaceX, StubHub to launch IPO: Morning Buzz
- Morning Movers: EchoStar jumps following $17B spectrum deal with SpaceX
- Rapport Therapeutics price target raised to $34 from $31 at H.C. Wainwright
- Rapport Therapeutics Reports Positive Phase 2a Trial Results